the ADME Tox specialists
welcome to cyprotex

Investor News

August 30, 2007 - Interim results for the six months to 30 June 2007

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, today reports its Interim Results for the half year ended 30 June 2007.

• Despite experiencing the disruptive effects of two major and exceptional events during the first six months of 2007, the Group reports a year-on-year revenue improvement, whilst its customer base expanded at a record level.

• Revenues for the period increased approximately 4% to £1.69m (1H 2006: £1.62m).

• Gross Profits rose by 1.6% to £1.44m (1H 2006: £1.41m).

• A Requisition to unseat present management and, for unconnected reasons, internal reorganisation of the Group’s single largest customer, hindered progress during the second quarter. Lost momentum is now being recaptured.

• Management reiterates its confidence in Cyprotex’ business activity, its global market opportunity and the real value of its unique technologies, whilst retaining adequate cash resources and facilities.

Commenting on the results, Robert Morrisson Atwater, Chairman and Chief Executive Officer of Cyprotex PLC, said: “The market opportunity for Cyprotex’s unique technologies is clear. We are confident of growing the Company’s revenue in the second half of 2007, regaining some of the momentum lost in the first half of the year”.

For further information:

Cyprotex PLC
Robert Morrison Atwater, Chief Executive Officer
Tel: +44 1625 505 100

Russell Gibbs, Chief Financial Officer

Noumura Code Securities Limited
Charles Walker
Tel: +44 20 7776 1206

Media Enquiries:
MC Communications Limited

Alex Glover
Tel: +44 20 7930 9030

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

This website was last updated
on 21st July 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.